Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients

Int Clin Psychopharmacol. 2011 Sep;26(5):252-62. doi: 10.1097/YIC.0b013e328349b117.

Abstract

Agomelatine, an MT1/MT2 receptor agonist and 5-HT2C receptor antagonist antidepressant, is known to have beneficial effects on subjective sleep in major depressive disorder patients. This international multicenter, randomized, double-blind study compared the effects of agomelatine (25-50 mg/day) and escitalopram (10-20 mg/day) on sleep polysomnographic parameters in major depressive disorder patients treated up to 24 weeks. A total of 138 outpatients were randomly allocated to agomelatine (n=71) or escitalopram (n=67). Treatment with agomelatine was associated with a reduction in sleep latency from week 2 onward. The difference between treatments was significant on all evaluations. Rapid eye movement latency was increased with escitalopram compared with agomelatine, with significant between-group differences at every visit. Agomelatine preserved the number of sleep cycles, whereas it was decreased with escitalopram with significant between-group differences at every visit. Assessments on visual analogue scales indicated that treatment with agomelatine improved morning condition, and reduced daytime sleepiness compared with escitalopram.17-item Hamilton depression rating scale total score was reduced in both groups, agomelatine was statistically noninferior to escitalopram at 6 weeks. Both treatments were well tolerated. This study showed that the clinical effects of agomelatine on sleep and wake parameters are different from that of escitalopram.

Publication types

  • Comparative Study
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetamides / pharmacology
  • Acetamides / therapeutic use*
  • Adult
  • Citalopram / pharmacology
  • Citalopram / therapeutic use*
  • Depressive Disorder, Major / drug therapy*
  • Depressive Disorder, Major / psychology*
  • Double-Blind Method
  • Female
  • Humans
  • Hypnotics and Sedatives / therapeutic use
  • Male
  • Melatonin / agonists
  • Middle Aged
  • Polysomnography / methods
  • Serotonin Uptake Inhibitors / therapeutic use*
  • Sleep Stages / drug effects*
  • Sleep Stages / physiology
  • Treatment Outcome
  • Wakefulness / drug effects*
  • Wakefulness / physiology

Substances

  • Acetamides
  • Hypnotics and Sedatives
  • Serotonin Uptake Inhibitors
  • Citalopram
  • agomelatine
  • Melatonin